Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
Abstract
Cancer immunotherapy represents one of the most important innovations in modern medicine. Durvalumab is an anti-programmed cell death ligand 1 (PDL-1) agent which is currently under investigation in several studies in combination with the anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) drug tremelimumab. The aim of this review was to systematically identify and revise the current scientific literature investigating the combination of...
Paper Details
Title
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
Published Date
Jun 8, 2021
Journal
Volume
38
Issue
7
Pages
3674 - 3693
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History